Bio-Rad Laboratories Inc (BIO)vsEdwards Lifesciences Corp (EW)
BIO
Bio-Rad Laboratories Inc
$294.32
-4.28%
HEALTHCARE · Cap: $7.65B
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 143% more annual revenue ($6.30B vs $2.59B). EW leads profitability with a 17.4% profit margin vs 6.5%. BIO appears more attractively valued with a PEG of 1.19. EW earns a higher WallStSmart Score of 61/100 (C+).
BIO
Hold47
out of 100
Grade: D+
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.0%
Fair Value
$195.84
Current Price
$294.32
$98.48 premium
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
Areas to Watch
1.1% revenue growth
ROE of 2.5% — below average capital efficiency
6.5% margin — thin
Weak financial health signals
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BIO
The strongest argument for BIO centers on Price/Book, Altman Z-Score, Debt/Equity. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : BIO
The primary concerns for BIO are Revenue Growth, Return on Equity, Profit Margin. A P/E of 47.7x leaves little room for execution misses.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
BIO profiles as a value stock while EW is a growth play — different risk/reward profiles.
BIO carries more volatility with a beta of 1.08 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
BIO generates stronger free cash flow (78M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 47/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bio-Rad Laboratories Inc
HEALTHCARE · MEDICAL DEVICES · USA
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?